Kwanchai Pirojsakul1,2,3, Dev Desai1,3, Chantale Lacelle3, Mouin G Seikaly4,5. 1. Children's Medical Center, Dallas, TX, USA. 2. Pediatric Nephrology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3. UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9063, USA. 4. Children's Medical Center, Dallas, TX, USA. Mouin.Seikaly@UTSouthwestern.edu. 5. UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9063, USA. Mouin.Seikaly@UTSouthwestern.edu.
Abstract
BACKGROUND: Data on renal allograft outcome in sensitized children are scarce. We report the clinical courses of four children who received desensitization therapy prior to renal transplantation in our institution. METHODS: Between 2009 and 2011, four pediatric patients with stage 5 chronic kidney disease received desensitization therapy due to: (1) positive donor-specific antibodies (DSA) and/or crossmatches with potential living donors, (2) more than three positive crossmatches with deceased donors or (3) high calculated panel-reactive antibody of >80 %. Desensitization with rituximab, intravenous immunoglobulin and bortezomib was performed in all patients. Induction therapy included combinations of plasmapheresis and/or alemtuzumab or anti-thymocyte globulin. Standard post-transplant medications included tacrolimus, mycophenolate mofetil and prednisolone. RESULTS: Post-transplant screening revealed DSA in three patients. Biopsy showed no evidence of rejection at 1 month in two patients, one of whom developed chronic active antibody-mediated rejection 4.5 years later. One patient developed borderline acute cellular rejection at 1 month, but the serum creatinine level was stable and DSA disappeared without treatment 1 month later, with stable long-term allograft function at 3 years. Estimated or measured glomerular filtration rate of the patients ranged between 30 and 75 ml/min/1.73 m(2) after 1 to 4.5 years. CONCLUSIONS: The four sensitized patients reported here who received desensitization therapy had successful renal transplants with a low risk of immediate post-transplant rejection. Overall, long-term allograft functions and complications from immunosuppression were encouraging.
BACKGROUND: Data on renal allograft outcome in sensitized children are scarce. We report the clinical courses of four children who received desensitization therapy prior to renal transplantation in our institution. METHODS: Between 2009 and 2011, four pediatric patients with stage 5 chronic kidney disease received desensitization therapy due to: (1) positive donor-specific antibodies (DSA) and/or crossmatches with potential living donors, (2) more than three positive crossmatches with deceased donors or (3) high calculated panel-reactive antibody of >80 %. Desensitization with rituximab, intravenous immunoglobulin and bortezomib was performed in all patients. Induction therapy included combinations of plasmapheresis and/or alemtuzumab or anti-thymocyte globulin. Standard post-transplant medications included tacrolimus, mycophenolate mofetil and prednisolone. RESULTS: Post-transplant screening revealed DSA in three patients. Biopsy showed no evidence of rejection at 1 month in two patients, one of whom developed chronic active antibody-mediated rejection 4.5 years later. One patient developed borderline acute cellular rejection at 1 month, but the serum creatinine level was stable and DSA disappeared without treatment 1 month later, with stable long-term allograft function at 3 years. Estimated or measured glomerular filtration rate of the patients ranged between 30 and 75 ml/min/1.73 m(2) after 1 to 4.5 years. CONCLUSIONS: The four sensitized patients reported here who received desensitization therapy had successful renal transplants with a low risk of immediate post-transplant rejection. Overall, long-term allograft functions and complications from immunosuppression were encouraging.
Authors: Madhura Pradhan; Ryan M Raffaelli; Curt Lind; Kevin E C Meyers; Bernard S Kaplan; Hobart J Baluarte; Dimitri Monos Journal: Pediatr Transplant Date: 2008-04-22
Authors: Martin L Mai; Nasimul Ahsan; Hani M Wadei; Petrina V Genco; Xochiquetzal J Geiger; Darrin L Willingham; C Burcin Taner; Winston R Hewitt; Hani P Grewal; Justin H H Nguyen; Christopher B Hughes; Thomas A Gonwa Journal: Transplantation Date: 2009-01-27 Impact factor: 4.939
Authors: Annette M Jackson; Edward S Kraus; Babak J Orandi; Dorry L Segev; Robert A Montgomery; Andrea A Zachary Journal: Kidney Int Date: 2014-07-23 Impact factor: 10.612
Authors: Irene K Kim; Jua Choi; Ashley A Vo; Alexis Kang; Mitasha Patel; Mieko Toyoda; James Mirocha; Elaine S Kamil; J Louis Cohen; Sabrina Louie; Odette Galera; Stanley C Jordan; Dechu P Puliyanda Journal: Transplantation Date: 2017-04 Impact factor: 4.939